Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine a, and steroid elimination: 3-year data

Transplantation

Volumn 92, Issue 6, 2011, Pages 658-662

  Pape, Lars ^a   Lehner, Frank ^a   Blume, Cornelia ^a   Ahlenstiel, Thurid ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute rejection; Children; Everolimus; Kidney transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; PREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; CHILD GROWTH; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BIOPSY; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; PREDNISOLONE; RECOMBINANT FUSION PROTEINS; SIROLIMUS; STEROIDS; TIME FACTORS;

EID: 80052648009     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182295bed     Document Type: Article

References (26)

1. Joosten SA, Sijpkens W, van Kooten C, et al. Chronic renal allograft rejection: Pathophysiologic considerations. Kidney Int 2005; 68: 1.
2. Offner G, Toenshoff B, Höcker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycopheolate mofetil, and steroids. Transplantation 2008; 86: 1241.
3. https://web.emmes.com/study/ped/annlrept/annlrept.html. Accessed February 21, 2011.
4. Pape L, Ahlenstiel T, Ehrich JHH, et al. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Ped Transplant 2007; 11: 291.
5. Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: The emerging dualistic role of rapamycin. Transpl Int 2008; 21: 207.
6. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine a, basliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010; 10: 2349.
7. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629.
8. Jungraithmayr TC, Wiesmayr S, Staskewitz A, et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007; 83: 900.
9. Vítko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
10. McDonagh JE, Kelly DA. Trans-plan-sition! Transplantation and transition. Pediatr Transplant 2007; 11: 578.
11. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, et al. Growing pains: Non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005; 9: 381.
12. Watson AR. Problems and pitfalls of transition from paediatric to adult renal care. Pediatr Nephrol 2005; 20: 113.
13. Bell L. Adolescents with renal disease in an adult world: Meeting the challenge of transition of care. Nephrol Dial Transplant 2007; 22: 988.
14. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837.
15. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
16. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
17. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
18. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
19. Tenderich G, Fuchs U, Zittermann A, et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007; 21: 536.
20. Chapman JR, Valantine H, Albanell J. Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy. Transplant Proc 2007; 39: 2937.
21. Hartford CM, Retain MJ. Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007; 82: 281.
22. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 69.
23. Rangel GA, Ariceta G. Growth failure associated with sirolimus: Case report. Pediatr Nephrol 2009; 24: 2047.
24. Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: The TWIST study. Am J Transplant 2010; 10: 828.
25. Li L, Chang A, Naesens M, et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 2009; 9: 1362.
26. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350: 2654.